Altogether, these results indicated HOXB3 drove WNT-associated tumor progression and abiraterone resistance in CRPC xenograft, and antiandrogen combined with HOXB3 suppression could be potential therapy for CRPC with WNT-pathway activation (Fig. 7G). The gene discussed is HOXB3; the disease is neoplasm.